“…ICAM-1 is constitutively expressed on a variety of inflammatory and immune effector cells and in structural cells, such as: endothelial cells, fibroblasts, and epithelial cells [3]. In addition, ICAM-1 has been detected on the surface of a variety of primary tumours and tumour cell lines, including lymphomas [4], melanomas [5], renal [6], pancreatic [7], bladder [8] and lung carcinomas [9]. Because LFA-1 is expressed on mononuclear phagocytes, cytotoxic T-cells, natural-killer (NK), and lymphokine-activated killer (LAK) cells [1], the expression of ICAM-1 by tumour cells may be involved in the regulation of their susceptibility to cytotoxic activity of autologous and allogeneic defensive cells.…”